BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6608957)

  • 21. Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide.
    Lu ZX; Fok KF; Erickson BW; Hugli TE
    J Biol Chem; 1984 Jun; 259(12):7367-70. PubMed ID: 6610676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The primary structure of porcine C3a anaphylatoxin.
    Corbin NC; Hugli TE
    J Immunol; 1976 Sep; 117(3):990-5. PubMed ID: 956663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
    Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
    Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing synthetic superagonists of C3a anaphylatoxin.
    Ember JA; Johansen NL; Hugli TE
    Biochemistry; 1991 Apr; 30(15):3603-12. PubMed ID: 2015217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.
    Fernandez HN; Hugli TE
    J Immunol; 1976 Nov; 117(5 Pt 1):1688-94. PubMed ID: 1002996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C4a: the third anaphylatoxin of the human complement system.
    Gorski JP; Hugli TE; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5299-302. PubMed ID: 291947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of humoral immune responses by synthetic C3a peptides.
    Morgan EL; Weigle WO; Erickson BW; Fok KF; Hugli TE
    J Immunol; 1983 Nov; 131(5):2258-61. PubMed ID: 6355293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of the anaphylatoxins C3a and C5a on isolated mast cells from rat and man.
    Jürgensen H; Behrendt H; Damerau B; Schmutzler W
    Agents Actions; 1986 Apr; 18(1-2):153-4. PubMed ID: 2425572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaphylatoxin-induced release of histamine from in vitro perfused guinea pig kidney.
    Abdullah NA; Assem ES; Damerau B
    Agents Actions; 1988 Apr; 23(3-4):181-4. PubMed ID: 2455983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a.
    Hugli TE
    Crit Rev Immunol; 1981 Feb; 1(4):321-66. PubMed ID: 7037298
    [No Abstract]   [Full Text] [Related]  

  • 31. Angiography and complement activation. Evidence for generation of C3a anaphylatoxin by intravascular contrast agents.
    Westaby S; Dawson P; Turner MW; Pridie RB
    Cardiovasc Res; 1985 Feb; 19(2):85-8. PubMed ID: 3872180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.
    Fernandez HN; Hugli TE
    J Biol Chem; 1978 Oct; 253(19):6955-64. PubMed ID: 690134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaphylatoxins: C3a and C5a.
    Hugli TE; Müller-Eberhard HJ
    Adv Immunol; 1978; 26():1-53. PubMed ID: 358800
    [No Abstract]   [Full Text] [Related]  

  • 34. Chemotactic effects of the complement-derived peptides C3a, C3ai and C5a (classical anaphylatoxin) on rabbit and guinea-pig polymorphonuclear leukocytes.
    Damerau B; Grünefeld E; Vogt W
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Nov; 305(2):181-4. PubMed ID: 732894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mast cells are not required for anaphylatoxin-induced ileal smooth muscle contraction.
    Stimler-Gerard NP; Galli SJ
    J Immunol; 1987 Mar; 138(6):1908-13. PubMed ID: 2434565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized.
    Ganu VS; Müller-Eberhard HJ; Hugli TE
    Mol Immunol; 1989 Oct; 26(10):939-48. PubMed ID: 2531841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of casoxin C, an ileum-contracting peptide derived from bovine kappa-casein, as an agonist for C3a receptors.
    Takahashi M; Moriguchi S; Suganuma H; Shiota A; Tani F; Usui H; Kurahashi K; Sasaki R; Yoshikawa M
    Peptides; 1997; 18(3):329-36. PubMed ID: 9145417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaphylatoxin binding and degradation by rat peritoneal mast cells. Mechanisms of degranulation and control.
    Fukuoka Y; Hugli TE
    J Immunol; 1990 Sep; 145(6):1851-8. PubMed ID: 1697312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses.
    Morgan EL; Weigle WO; Hugli TE
    J Exp Med; 1982 May; 155(5):1412-26. PubMed ID: 6978374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low zone desensitization: a stimulus-specific control mechanism of cell response. Investigations on anaphylatoxin-induced platelet secretion.
    Meuer S; Zanker B; Hadding U; Bitter-Suermann D
    J Exp Med; 1982 Mar; 155(3):698-710. PubMed ID: 6977607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.